vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PARK NATIONAL CORP (PRK). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $168.3M, roughly 1.0× PARK NATIONAL CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
ESPR vs PRK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $168.3M |
| Net Profit | — | $42.6M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 25.3% |
| Revenue YoY | 143.7% | 2.2% |
| Net Profit YoY | — | 10.4% |
| EPS (diluted) | $0.32 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $168.3M | ||
| Q3 25 | $87.3M | $169.5M | ||
| Q2 25 | $82.4M | $168.7M | ||
| Q1 25 | $65.0M | $157.9M | ||
| Q4 24 | $69.1M | $164.7M | ||
| Q3 24 | $51.6M | $170.3M | ||
| Q2 24 | $73.8M | $157.7M | ||
| Q1 24 | $137.7M | $152.8M |
| Q4 25 | — | $42.6M | ||
| Q3 25 | $-31.3M | $47.2M | ||
| Q2 25 | $-12.7M | $48.1M | ||
| Q1 25 | $-40.5M | $42.2M | ||
| Q4 24 | — | $38.6M | ||
| Q3 24 | $-29.5M | $38.2M | ||
| Q2 24 | $-61.9M | $39.4M | ||
| Q1 24 | $61.0M | $35.2M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | 34.3% | ||
| Q2 25 | 8.6% | 35.2% | ||
| Q1 25 | -34.0% | 32.4% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 27.4% | ||
| Q2 24 | 3.5% | 30.6% | ||
| Q1 24 | 52.5% | 27.8% |
| Q4 25 | — | 25.3% | ||
| Q3 25 | -35.9% | 27.8% | ||
| Q2 25 | -15.4% | 28.5% | ||
| Q1 25 | -62.2% | 26.7% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | -57.2% | 22.4% | ||
| Q2 24 | -83.9% | 25.0% | ||
| Q1 24 | 44.3% | 23.0% |
| Q4 25 | $0.32 | $2.62 | ||
| Q3 25 | $-0.16 | $2.92 | ||
| Q2 25 | $-0.06 | $2.97 | ||
| Q1 25 | $-0.21 | $2.60 | ||
| Q4 24 | $-0.14 | $2.38 | ||
| Q3 24 | $-0.15 | $2.35 | ||
| Q2 24 | $-0.33 | $2.42 | ||
| Q1 24 | $0.34 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $233.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.4B |
| Total Assets | $465.9M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $233.5M | ||
| Q3 25 | $92.4M | $218.9M | ||
| Q2 25 | $86.1M | $193.1M | ||
| Q1 25 | $114.6M | $237.6M | ||
| Q4 24 | $144.8M | $160.6M | ||
| Q3 24 | $144.7M | $201.7M | ||
| Q2 24 | $189.3M | $261.5M | ||
| Q1 24 | $226.6M | $306.1M |
| Q4 25 | $-302.0M | $1.4B | ||
| Q3 25 | $-451.4M | $1.3B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.2B | ||
| Q3 24 | $-370.2M | $1.2B | ||
| Q2 24 | $-344.2M | $1.2B | ||
| Q1 24 | $-294.3M | $1.2B |
| Q4 25 | $465.9M | $9.8B | ||
| Q3 25 | $364.0M | $9.9B | ||
| Q2 25 | $347.1M | $9.9B | ||
| Q1 25 | $324.0M | $9.9B | ||
| Q4 24 | $343.8M | $9.8B | ||
| Q3 24 | $314.1M | $9.9B | ||
| Q2 24 | $352.3M | $9.9B | ||
| Q1 24 | $373.1M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $198.3M |
| Free Cash FlowOCF − Capex | — | $191.9M |
| FCF MarginFCF / Revenue | — | 114.1% |
| Capex IntensityCapex / Revenue | 0.0% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 4.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $328.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $198.3M | ||
| Q3 25 | $-4.3M | $52.6M | ||
| Q2 25 | $-31.4M | $49.7M | ||
| Q1 25 | $-22.6M | $37.9M | ||
| Q4 24 | $-35.0M | $178.8M | ||
| Q3 24 | $-35.3M | $43.8M | ||
| Q2 24 | $-7.2M | $50.9M | ||
| Q1 24 | $53.8M | $35.0M |
| Q4 25 | — | $191.9M | ||
| Q3 25 | — | $51.1M | ||
| Q2 25 | — | $48.4M | ||
| Q1 25 | — | $36.8M | ||
| Q4 24 | — | $169.7M | ||
| Q3 24 | $-35.5M | $41.7M | ||
| Q2 24 | $-7.3M | $49.0M | ||
| Q1 24 | $53.8M | $31.9M |
| Q4 25 | — | 114.1% | ||
| Q3 25 | — | 30.1% | ||
| Q2 25 | — | 28.7% | ||
| Q1 25 | — | 23.3% | ||
| Q4 24 | — | 103.0% | ||
| Q3 24 | -68.7% | 24.5% | ||
| Q2 24 | -9.9% | 31.1% | ||
| Q1 24 | 39.0% | 20.8% |
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 5.6% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.1% | 1.2% | ||
| Q1 24 | 0.1% | 2.1% |
| Q4 25 | — | 4.65× | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 4.63× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | 0.88× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRK
Segment breakdown not available.
